Genetic Analysis（8V8）株式概要Genetic Analysis AS社は、科学的根拠に基づく診断会社で、米国、欧州、および国際的なヒトマイクロバイオーム市場向けの診断ソリューションを開発している。 詳細8V8 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6報酬過去5年間の収益は年間15.7%増加しました。 リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( €43M )意味のある収益がありません ( NOK21M )すべてのリスクチェックを見る8V8 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.03981.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-29m42m2016201920222025202620282031Revenue NOK 42.5mEarnings NOK 7.7mAdvancedSet Fair ValueView all narrativesGenetic Analysis AS 競合他社DarwinSymbol: MUN:7V0Market cap: €74.4mFormyconSymbol: XTRA:FYBMarket cap: €347.4mDextech MedicalSymbol: DB:LQ0Market cap: €184.5mHeidelberg PharmaSymbol: XTRA:HPHAMarket cap: €128.7m価格と性能株価の高値、安値、推移の概要Genetic Analysis過去の株価現在の株価€0.03952週高値€0.1352週安値€0.035ベータ2.11ヶ月の変化-3.92%3ヶ月変化-10.91%1年変化-68.89%3年間の変化-64.84%5年間の変化n/aIPOからの変化-96.16%最新ニュースBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Chairman of the Board Morten Jurs was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29Genetic Analysis AS to Report Q1, 2026 Results on May 28, 2026Genetic Analysis AS announced that they will report Q1, 2026 results on May 28, 2026お知らせ • Mar 13Genetic Analysis AS Launches GA-Map Dysbiosis Test AInsight for AI-Assisted InterpretationGenetic Analysis AS announced the launch of GA-map Dysbiosis Test AInsight, an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice. The GA-map Dysbiosis Test is a CE-marked molecular diagnostic assay designed to profile gut microbiome and evaluate intestinal dysbiosis by comparing a patient's microbiome profile to a healthy reference population. AInsight supports healthcare professionals by structuring microbiome findings and contextualizing deviations in bacterial abundance using curated scientific evidence. The platform utilizes an AI language model to retrieve clinically relevant associations linked to each bacterial marker measured by the GA-map Dysbiosis Test. By simplifying the interpretation of microbiome results, AInsight is expected to support the broader clinical use of the GA-map Dysbiosis Test and contribute to increased demand for GA's reagent kit products. Similar to the GA-map Dysbiosis Test, which operates within a predefined and clinically validated closed diagnostic system, the AI model deployed in AInsight is restricted to retrieving information exclusively from GA's Bacteria Compendium - GA's curated knowledge base. This controlled framework ensures that generated interpretation reports remain aligned with the validated scientific foundation underpinning the GA-map Dysbiosis Test. The addition of AInsight enables automated generation of structured interpretation reports for individual microbiome profiles and supports scalable report generation for laboratory workflows, enabling laboratories to efficiently handle increasing testing volumes. The reports generated by GA-map Dysbiosis Test AInsight are intended to provide informational support and should always be interpreted within the broader clinical context by qualified healthcare professionals. By lowering the barrier to interpreting microbiome test results, AInsight represents an important step in GA's strategy to expand the clinical use of its GA-map diagnostic platform.お知らせ • Jan 27Genetic Analysis AS to Report Fiscal Year 2025 Results on Feb 25, 2026Genetic Analysis AS announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Feb 25, 2026お知らせ • Nov 17Genetic Analysis AS Announces Completion of the Biomarker Panel Development in Its Ongoing IBD Precision Dx ProjectGenetic Analysis AS announced the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marks a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development. The goal of the IBD Precision Dx project is to develop a microbiome-based diagnostic test capable of predicting disease course in Ulcerative Colitis (UC) patients, thereby supporting earlier and more targeted treatment decisions. The project is conducted in collaboration with two Scandinavian university hospitals, Akershus University Hospital (AHUS) and University hospital of Gothenburg (UGOT) and supported by funding of approximately EUR 2 million from the Research Council of Norway. GA has now finalized the bacteria biomarker panel design freeze, marking the completion of the assay development phase. The resulting biomarker panel enables analysis of the bacterial profile in stool samples to stratify UC patients according to predicted disease severity. Testing performed using this panel demonstrates strong technical results. GA has extensive experience in IBD research, having been actively involved in the field since 2013. Over the years, the company has built an extensive knowledge base, providing valuable insight that has played a key role in designing and conducting this IBD project, ultimately leading up to the development of the GA-map® IBD Precision Dx. The new assay will leverage GA's proprietary GA-map® technology platform for standardized, multiplex analysis adapted on the Luminex® xMAP® technology. This approach will enable commercialization of the assay on the Lumine xMAP® platform and make it available to laboratories and research users worldwide. Clinical need and market relevance: IBD affects approximately 5-6 million people across the US and Europe and imposes a significant burden on patients and healthcare systems, with annual healthcare costs estimated at EUR 12-13 billion2). Beyond healthcare costs, IBD has profound impacts on patients' quality of life, productivity, and social functioning. More than half of IBD patients are diagnosed with UC3). There is a recognized need for improved tools to support personalized treatment strategies and optimize therapy selection. Currently, no diagnostic tool exists to predict whether an UC patient will experience a mild or severe disease course. As a result, treatment optimization remains an unmet clinical need. Early administration of biologic therapy in high-risk patients is associated with better outcomes, underscoring the importance of early, precise disease course prediction. The GA-map®IBD Precision Dx test aims to fill this gap by enabling personalized treatment strategies and improved patient outcomes.お知らせ • Oct 29Genetic Analysis AS to Report Q3, 2025 Results on Nov 27, 2025Genetic Analysis AS announced that they will report Q3, 2025 results on Nov 27, 2025最新情報をもっと見るRecent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Chairman of the Board Morten Jurs was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29Genetic Analysis AS to Report Q1, 2026 Results on May 28, 2026Genetic Analysis AS announced that they will report Q1, 2026 results on May 28, 2026お知らせ • Mar 13Genetic Analysis AS Launches GA-Map Dysbiosis Test AInsight for AI-Assisted InterpretationGenetic Analysis AS announced the launch of GA-map Dysbiosis Test AInsight, an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice. The GA-map Dysbiosis Test is a CE-marked molecular diagnostic assay designed to profile gut microbiome and evaluate intestinal dysbiosis by comparing a patient's microbiome profile to a healthy reference population. AInsight supports healthcare professionals by structuring microbiome findings and contextualizing deviations in bacterial abundance using curated scientific evidence. The platform utilizes an AI language model to retrieve clinically relevant associations linked to each bacterial marker measured by the GA-map Dysbiosis Test. By simplifying the interpretation of microbiome results, AInsight is expected to support the broader clinical use of the GA-map Dysbiosis Test and contribute to increased demand for GA's reagent kit products. Similar to the GA-map Dysbiosis Test, which operates within a predefined and clinically validated closed diagnostic system, the AI model deployed in AInsight is restricted to retrieving information exclusively from GA's Bacteria Compendium - GA's curated knowledge base. This controlled framework ensures that generated interpretation reports remain aligned with the validated scientific foundation underpinning the GA-map Dysbiosis Test. The addition of AInsight enables automated generation of structured interpretation reports for individual microbiome profiles and supports scalable report generation for laboratory workflows, enabling laboratories to efficiently handle increasing testing volumes. The reports generated by GA-map Dysbiosis Test AInsight are intended to provide informational support and should always be interpreted within the broader clinical context by qualified healthcare professionals. By lowering the barrier to interpreting microbiome test results, AInsight represents an important step in GA's strategy to expand the clinical use of its GA-map diagnostic platform.お知らせ • Jan 27Genetic Analysis AS to Report Fiscal Year 2025 Results on Feb 25, 2026Genetic Analysis AS announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Feb 25, 2026お知らせ • Nov 17Genetic Analysis AS Announces Completion of the Biomarker Panel Development in Its Ongoing IBD Precision Dx ProjectGenetic Analysis AS announced the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marks a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development. The goal of the IBD Precision Dx project is to develop a microbiome-based diagnostic test capable of predicting disease course in Ulcerative Colitis (UC) patients, thereby supporting earlier and more targeted treatment decisions. The project is conducted in collaboration with two Scandinavian university hospitals, Akershus University Hospital (AHUS) and University hospital of Gothenburg (UGOT) and supported by funding of approximately EUR 2 million from the Research Council of Norway. GA has now finalized the bacteria biomarker panel design freeze, marking the completion of the assay development phase. The resulting biomarker panel enables analysis of the bacterial profile in stool samples to stratify UC patients according to predicted disease severity. Testing performed using this panel demonstrates strong technical results. GA has extensive experience in IBD research, having been actively involved in the field since 2013. Over the years, the company has built an extensive knowledge base, providing valuable insight that has played a key role in designing and conducting this IBD project, ultimately leading up to the development of the GA-map® IBD Precision Dx. The new assay will leverage GA's proprietary GA-map® technology platform for standardized, multiplex analysis adapted on the Luminex® xMAP® technology. This approach will enable commercialization of the assay on the Lumine xMAP® platform and make it available to laboratories and research users worldwide. Clinical need and market relevance: IBD affects approximately 5-6 million people across the US and Europe and imposes a significant burden on patients and healthcare systems, with annual healthcare costs estimated at EUR 12-13 billion2). Beyond healthcare costs, IBD has profound impacts on patients' quality of life, productivity, and social functioning. More than half of IBD patients are diagnosed with UC3). There is a recognized need for improved tools to support personalized treatment strategies and optimize therapy selection. Currently, no diagnostic tool exists to predict whether an UC patient will experience a mild or severe disease course. As a result, treatment optimization remains an unmet clinical need. Early administration of biologic therapy in high-risk patients is associated with better outcomes, underscoring the importance of early, precise disease course prediction. The GA-map®IBD Precision Dx test aims to fill this gap by enabling personalized treatment strategies and improved patient outcomes.お知らせ • Oct 29Genetic Analysis AS to Report Q3, 2025 Results on Nov 27, 2025Genetic Analysis AS announced that they will report Q3, 2025 results on Nov 27, 2025お知らせ • Sep 24Genetic Analysis AS Launches GA-map MHI GutHealth Reagent KitGenetic Analysis AS announced the launch of a novel Research Use Only (RUO) reagent kit, the GA-map MHI GutHealth. The test provides an advanced tool for measuring antibiotic-induced microbiome imbalances and has been validated for recurrent Clostridioides difficile infection (rCDI). With this launch, GA-map MHI Gut Health is made available for Luminex xMAP users globally. As communicated on December 20, 2024, GA and Ferring Pharmaceuticals announced a collaboration to develop a new microbiome diagnostic test. Since then, GA has brought together two established technologies - GA's PCR-based microbiome diagnostic platform (GA-map®?1) and Ferring's research-validated biomarker for measuring post-antibiotic microbiome imbalances (the 'Microbiome Health Index(TM)'2). The test utilizes the unique Luminex xMAP®? technology for targeted and effective multiplex analysis, making it readily accessible for LuminexxMAP users worldwide. Initially, GA-map®? MHI GutHealth is targeted towards rCDI patients, providing clinicians with a rapid tool to assess baseline microbiome imbalances and monitor treatment effects during microbiome restoration. The test also has potential as a pharmacodynamic (PD) measure of microbiota restoration in clinical trials for Live Biotherapeutic Products (LBPs), Fecal Microbiota Transplants (FMTs), and other microbiome restoration approaches. This is relevant in all clinical trials where antibiotic-associated microbiome imbalances play a critical role, such as Graft-versus-Host Disease (GvHD), infectious diseases, immunocompromised patients, and MDRO-colonized patients3. With the launch of the GA-map®?MHI GutHealth test, GA expands into a novel diagnostic field. The market potential for a diagnostic test aiding treatment and follow-up of rCDI is significant, with close to 500,000 annual CDI cases in the US alone4. Thus, the test will contribute to Genetic Analysis' commercial activities and provide incremental contribution to the Company's revenue base.お知らせ • Jul 31Genetic Analysis AS and Pangea Laboratory LLC Announces the Launch of GA-Map MHI GutHealth in the USAGenetic Analysis AS and Pangea Laboratory LLC announced the launch of the GA-map MHI GutHealth as a Research Use Only (RUO) test in the USA. As part of the collaboration Pangea will perform analysis in their CLIA-certified, CAP-accredited laboratory in Tustin, California. The GA-map MH I GutHealth is the first microbiome-based diagnostic test providing clinically actionable insights into antibiotic-induced microbiome imbalances. The test has been developed by GA in collaboration with Ferring Pharmaceuticals and combines GA's proprietary GA-map technology with Ferring's Microbiome Health Index(TM). MHI is a validated biomarker measuring the ratio of pro-inflammatory versus anti-inflammatory bacteria in the patient's gut, demonstrated in recurrent Clostridioides difficile (rCDI) infected patients. Initially the test will be targeted towards patients with rCDI, providing clinicians with a rapid tool for baseline microbiome imbalance assessment and for monitoring the effect during microbiome restoration treatment. rCDI infection impacts approximately 500,000 patients annually in the United States, and up to 35% of initial CDI cases will experience a recurrence, which is associated with up to 30,000 deaths annually. Beyond rCDI, the test has the potential to support clinical decision-making in patient groups where antibiotic-associated microbiome imbalance plays a critical role.raft-versus-Host Disease (GvHD), infectious diseases, immunocompromised patients and patients colonized with multidrug-resistant organisms. The test will now be available for analysis at Pangea. As part of the collaboration, GA will supply reagent kits to Pangea. The agreement outlines an ongoing partnership without predefined order volumes or minimum delivery commitments. Revenues for GA will be generated based on the number of tests sold. GA is not obliged to make any additional financial investments as part of the collaboration.お知らせ • Jul 28Genetic Analysis AS to Report Q2, 2025 Results on Aug 27, 2025Genetic Analysis AS announced that they will report Q2, 2025 results on Aug 27, 2025お知らせ • Jun 17Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 4.139347 million.Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 4.139347 million. Security Name: Shares Security Type: Common Stock Securities Offered: 4,813,194 Price\Range: NOK 0.86 Transaction Features: Rights Offeringお知らせ • May 28Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of SEK 7.1 million.Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of SEK 7.1 million. Security Name: Shares Security Type: Common Stock Securities Offered: 8,255,814 Price\Range: SEK 0.86 Transaction Features: Rights Offeringお知らせ • May 06Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 12.805035 million.Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 12.805035 million. Security Name: Shares Security Type: Common Stock Securities Offered: 14,889,576 Price\Range: NOK 0.86 Transaction Features: Subsequent Direct Listingお知らせ • May 05Genetic Analysis as Announces Stepping Down of Jethro Holter as Current ChairmanGenetic Analysis AS announced that Dr. Jethro Holter, the current Chairman, to step down from his role and not seek re-election. Dr. Holter will be focusing on his new position as CEO of AdjuTec Pharma.お知らせ • Apr 28Genetic Analysis AS to Report Q1, 2025 Results on May 27, 2025Genetic Analysis AS announced that they will report Q1, 2025 results on May 27, 2025お知らせ • Apr 22Genetic Analysis AS and Thalys Medical Technology Group Announce the Launch of A Microbiome Test to the Chinese Consumer Health MarketGenetic Analysis AS ("GA") and Thalys Medical Technology Group Corporation ("Thalys") announced the launch of a microbiome test for the Consumer Health (D2C) market in China. The test is based on GA's clinically validated microbiome test, the GA-map® Dysbiosis Test, but specifically adapted to suit the Chinese market. This strategic cooperation represents the launch of GA's commercial presence in the fast-growing market Chinese market via its partner Thalys and their new Independent Clinical Lab (ICL) in Shanghai. The Chinese D2C microbiome testing market is growing rapidly. The estimated market size in 2023 was ~USD50-80 million, and with a projected CAGR of 20-30%, it has an expected 2030 Market Size of USD200-300 million. Main growth drivers include increased consumer interest in gut health, probiotics and personalized nutrition, as well as advances in e-commerce & digital health platforms such as Tmall and WeChat. The Thalys microbiome testing service powered by the GA-map® Dysbiosis Test will provide consumers in China with a fast and affordable test. Thalys has developed a D2C mobile software where customers can easily subscribe, pay and view report results on their mobile phones. The results will offer insights into the beneficial and potentially harmful microbes present in the gut, along with potential health- and wellness implications. Test results will include personalized probiotics recommendations as well as weight management & metabolic health insights. The upcoming launch of the GA-map® Dysbiosis Test to the Chinese Consumer Health market marks the completion of the first stage of the Thalys and GA collaboration. Moving forward, the Thalys Group will further develop and distribute tests based on GA's GA-map® Technology in China. Within the framework of the cooperation, GA will supply reagent kits to Thalys. Thalys has invested in the clinical study activities associated with the project and developing front-end consumer software solutions, whereas GA has contributed its proprietary software and algorithm development from internal resources. The agreement set out for the cooperation is structured as an ongoing partnership without predefined order volumes or minimum delivery commitments, but revenues will be generated for GA based on the number of tests sold. GA is not obliged to make any additional financial investments as part of the collaboration.お知らせ • Jan 28Genetic Analysis AS to Report Fiscal Year 2024 Results on Feb 26, 2025Genetic Analysis AS announced that they will report fiscal year 2024 results on Feb 26, 2025Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.065 loss per share (vs kr0.17 loss in 3Q 2023)Third quarter 2024 results: kr0.065 loss per share (improved from kr0.17 loss in 3Q 2023). Revenue: kr3.62m (down 24% from 3Q 2023). Net loss: kr3.23m (loss narrowed 25% from 3Q 2023).お知らせ • Oct 17Genetic Analysis AS to Report Q3, 2024 Results on Nov 15, 2024Genetic Analysis AS announced that they will report Q3, 2024 results on Nov 15, 2024お知らせ • Aug 01Genetic Analysis AS to Report Q2, 2024 Results on Aug 30, 2024Genetic Analysis AS announced that they will report Q2, 2024 results on Aug 30, 2024お知らせ • Jun 09Genetic Analysis as Announces Resignation of Eilert Aamodt as Chief Financial OfficerMicrobiome DX company Genetic Analysis AS announced that Eilert Aamodt has decided to resign as CFO to take on a new position in another company and industry. He will remain in his current role until the end of August 2024, ensuring a smooth and efficient transition for GA. Aamodt has been with GA since February 2021, and GA has initiated a process to recruit his replacement.Reported Earnings • May 30First quarter 2024 earnings released: kr0.14 loss per share (vs kr0.29 loss in 1Q 2023)First quarter 2024 results: kr0.14 loss per share (improved from kr0.29 loss in 1Q 2023). Revenue: kr4.77m (down 25% from 1Q 2023). Net loss: kr5.80m (loss narrowed 21% from 1Q 2023).お知らせ • May 01Genetic Analysis AS to Report Q1, 2024 Results on May 29, 2024Genetic Analysis AS announced that they will report Q1, 2024 results on May 29, 2024Reported Earnings • Apr 22Full year 2023 earnings released: kr0.62 loss per share (vs kr1.13 loss in FY 2022)Full year 2023 results: kr0.62 loss per share (improved from kr1.13 loss in FY 2022). Revenue: kr23.2m (up 12% from FY 2022). Net loss: kr23.8m (loss narrowed 16% from FY 2022).お知らせ • Apr 16Genetic Analysis AS, Annual General Meeting, May 14, 2024Genetic Analysis AS, Annual General Meeting, May 14, 2024.New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Market cap is less than US$10m (€2.18m market cap, or US$2.36m). Minor Risk Revenue is less than US$5m (kr23m revenue, or US$2.2m).お知らせ • Jan 31Genetic Analysis AS to Report Fiscal Year 2023 Results on Feb 29, 2024Genetic Analysis AS announced that they will report fiscal year 2023 results on Feb 29, 2024お知らせ • Dec 23Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 3.235125 million.Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 3.235125 million. Security Name: Shares Security Type: Common Stock Securities Offered: 4,095,095 Price\Range: NOK 0.79 Transaction Features: Rights OfferingNew Risk • Nov 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 9.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (€2.99m market cap, or US$3.20m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m).お知らせ • Nov 05Genetic Analysis AS Provides Earnings Guidance for the Year 2023, 2024, and 2025Genetic Analysis AS provided earnings guidance for the year 2023, 2024, and 2025. For 2023, the company expects Operating income of approximately NOK 20 million- NOK 25 million.For 2024, the company expects Operating income of approximately NOK 25 million - NOK 35 million.For 2025, the company expects Operating income of approximately NOK 40 million -NOK 60 million as well as positive cash flow.お知らせ • Nov 04Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of NOK 9 million.Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of NOK 9 million. Security Name: Shares Security Type: Common Stock Securities Offered: 11,392,405 Price\Range: NOK 0.79 Transaction Features: Rights OfferingReported Earnings • Nov 04Third quarter 2023 earnings released: kr0.17 loss per share (vs kr0.27 loss in 3Q 2022)Third quarter 2023 results: kr0.17 loss per share (improved from kr0.27 loss in 3Q 2022). Revenue: kr4.73m (flat on 3Q 2022). Net loss: kr4.32m (loss narrowed 35% from 3Q 2022).お知らせ • Nov 03Genetic Analysis AS Announces Resignation of Staffan Strömberg from the Board of DirectorsGenetic Analysis AS announced that the board member Staffan Strömberg has resigned from the Board of Directors ("BoD") at his request, due to high workload, with immediate effect.お知らせ • Oct 24Genetic Analysis AS Launches the GA-map® Discovery - New Microbiome Profiling Service Offering Directed to Research Customers in the Academia and Microbiome IndustryGenetic Analysis AS announced that the Company launches the GA-map® Discovery - a new microbiome profiling service offering directed to research customers in the academia and microbiome industry. The GA-map® Discovery is GA's first dedicated offering in the research market which is currently witnessing considerable growth - cementing GA's position as a pioneer in microbiome disease diagnostics. Built on the standardized GA-map® platform, GA-map® Discovery is a comprehensive end-to-end microbiota research service for gut and oral microbiota profiling. Comprising more than 170 bacteria markers, the GA-map® Discovery was developed to facilitate the discovery of new biomarkers and bacteria signatures associated with health and disease. GA-map® Discovery is a perfect choice for comparative studies of different disease cohorts, treatment responses, and more. The launch of GA-map ® Discovery brings to the market a research service with high accuracy, exceptional reproducibility, and short turnaround time, enabling cost-effective microbiota measurements. The GA-map® Discovery is GA's first dedicated offering in the research market. In recent years, microbiome research has witnessed considerable growth, fuelling new inventions in disease diagnostics, treatment selection and monitoring, and disease prevention. The research market for microbiome measurement was valued at $859 million in 2021 and is projected to reach $3,417 million by 2031.お知らせ • Oct 18Genetic Analysis AS to Report Nine Months, 2023 Results on Nov 16, 2023Genetic Analysis AS announced that they will report nine months, 2023 results on Nov 16, 2023New Risk • Oct 12New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr20m free cash flow). Share price has been highly volatile over the past 3 months (9.0% average weekly change). Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (€2.33m market cap, or US$2.45m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.1m).Reported Earnings • Sep 01Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.24 loss in 2Q 2022)Second quarter 2023 results: kr0.22 loss per share (improved from kr0.24 loss in 2Q 2022). Revenue: kr5.70m (up 4.0% from 2Q 2022). Net loss: kr5.49m (loss narrowed 9.4% from 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.お知らせ • Aug 01Genetic Analysis AS to Report Q2, 2023 Results on Aug 30, 2023Genetic Analysis AS announced that they will report Q2, 2023 results on Aug 30, 2023お知らせ • May 12Genetic Analysis AS Announces Changes in Members of Nomination CommitteeGenetic Analysis AS held its Annual General Meeting on May 11, 2023 approved Svein Lien and Eilert Aamodt were elected as members of nomination committee.Breakeven Date Change • Apr 25Forecast breakeven date pushed back to 2025The analyst covering Genetic Analysis previously expected the company to break even in 2024. New forecast suggests losses will reduce by 58% per year to 2024. The company is expected to make a profit of kr4.00m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 13Forecast breakeven date pushed back to 2025The analyst covering Genetic Analysis previously expected the company to break even in 2024. New forecast suggests losses will reduce by 58% per year to 2024. The company is expected to make a profit of kr4.00m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule.Reported Earnings • Feb 18Full year 2022 earnings released: kr1.14 loss per share (vs kr1.16 loss in FY 2021)Full year 2022 results: kr1.14 loss per share (improved from kr1.16 loss in FY 2021). Revenue: kr20.7m (up 55% from FY 2021). Net loss: kr28.3m (loss narrowed 2.5% from FY 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.お知らせ • Feb 17Genetic Analysis AS, Annual General Meeting, May 11, 2023Genetic Analysis AS, Annual General Meeting, May 11, 2023.お知らせ • Jan 31Genetic Analysis AS Announces Executive ChangesGenetic Analysis AS announce that GA is strengthening and future-proofing the organization within business development, sales, andproduct development to be better positioned to harvest opportunities in the microbiome market. As diagnostics is now becoming a vital part of the treatment regime for gastroenterological disorders, GA believes that the microbiome diagnostic market will continue to rapidly increase in the coming years. Following the recent regulatory approval of microbiome-altering drugs in the US, GA also sees a significant increase in opportunitiesto add several new markers on the GA-map® platform. GA announce that GA's Chief Technology Officer Kari Furu has accepted the new position as Head of Business and Product Development. Kari and GA's development teams have developed innovative products for GA, and its product development within IBD attracted strong interest recently as a finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD. GA announce that Ms. Pranvera Hiseni has accepted the position of Development Manager, reporting to the Head of Business and Product Development, where she will be responsible for GA's development projects. Pranvera has worked in GA's development department with a key focus on platform development and has also been instrumental in building up the HumGut Database, a comprehensive human gut metagenome collection. After the implementation of the new organization, the management team will consist of: Ronny Hermansen (CEO); Eilert Aamodt (CFO); Cristina Casén (Senior VP Clinical & Medical Affairs); Lars Tiller (Head of Operations); Kari Furu (Head of Business and Product Development); Detlef Janke (Commercial Director). With these new organizational changes, the previous responsibilities of the CTO and CCO will be implemented under the Product and Software development team and the clinical team. The new organization will be implemented immediately.お知らせ • Jan 20Genetic Analysis as Achieves Thai Fda License for Ga-Map[®] Dysbiosis Test in ThailandGenetic Analysis AS ("GA") announced that Thailand Food and Drug Administration ("Thai FDA") authority have granted GA license for the GA-map® Dysbiosis Test in Thailand. GA has, in cooperation with its distributor Hausen Bernstein Co. Ltd. ("HB") filed for regulatory approval of the GA-map® Dysbiosis Test in 2022, and announce that the test has now been approved by the Thai FDA authorities for Clinical use in IBS and IBD patients. HB plans to launch the GA-map from their molecular lab in Bangkok and market the GA-map® products in wider Thailand. The market demand for gut microbiome assessments is rapidly increasing globally in private healthcare services, medical clinics, and academic research with a focus on identifying and categorizing the patient's microbiota. Together with HB, GA can now offer its Thai FDA-approved standardised gut microbiome testing platform to the Thai market to meet the growing interest and raise awareness of dysbiosis.お知らせ • Jan 19Genetic Analysis AS to Report Fiscal Year 2022 Results on Feb 17, 2023Genetic Analysis AS announced that they will report fiscal year 2022 results on Feb 17, 2023Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 8 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Anne Camilla Bondesson is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Nov 06Third quarter 2022 earnings released: kr0.27 loss per share (vs kr0.28 loss in 3Q 2021)Third quarter 2022 results: kr0.27 loss per share (improved from kr0.28 loss in 3Q 2021). Revenue: kr4.77m (up 106% from 3Q 2021). Net loss: kr6.68m (loss narrowed 2.3% from 3Q 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.Reported Earnings • Aug 20Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr5.48m (up 177% from 2Q 2021). Net loss: kr6.06m (loss narrowed 12% from 2Q 2021). Over the next year, revenue is forecast to grow 62%, compared to a 10% growth forecast for the Biotechs industry in Germany.お知らせ • May 02Genetic Analysis AS Announces Board ChangesGenetic Analysis AS at the AGM held on April 28, 2022, elected Per Matsson as Chairperson, Andrew Stapleton as Board member, Thorvald Steen as member of nomination committee.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chairperson Kathryn Baker was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 06Genetic Analysis Strengthens Its Management Team by Hiring Head of OperationsMicrobiome DX company Genetic Analysis AS announces that the Company has strengthened its management team by hiring Mr. Lars Tiller as Head of Operations. Lars Tiller will be responsible for manufacturing and logistics activities in GA. As a result of the increased market demand for the GA-map diagnostic kits, GA has now strengthened its organisation with expertise and know-how from scale-up in the fast-growing diagnostic industry. As Head of Operations, Mr. Lars Tiller will be responsible for manufacturing and logistics and will focus on production efficiency to secure that the Company is able to meet future manufacturing capacity in a cost-efficient way.Reported Earnings • Feb 20Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr1.16 loss per share (up from kr1.29 loss in FY 2020). Revenue: kr13.4m (up 78% from FY 2020). Net loss: kr29.0m (loss widened 31% from FY 2020). Revenue was in line with analyst estimates.お知らせ • Feb 01Genetic Analysis as Launches on a New Technology Platform, GA-map® Dysbiosis Test KitMicrobiome DX company Genetic Analysis AS launches GA-map® on a new platform; MAGPIX®. The MAGPIX® instrument is the most affordable instrument of the Luminex's xMAP® instruments and it enables up to 50 plex using MagPlex® Microspheres. The MAGPIX® system is already a widely used platform and a large number of laboratories have already installed this system for performing other tests. To launch the GA-map® Test on a new readout system will capture the large number of labs already having the system installed, and thus be of great importance for significantly increasing the addressable market for high precision GA-map® Microbiome test. The more affordable MAGPIX® system will also increase the market size for GA in terms of lowering the cost barrier to install the test platform. Potential customers have for some years asked for GA-map® on the MAGPIX® instrument system and GA has now completed the develop and CE-marked the GA-map® Test on this well-known and easy to use instrument. This will complement GA's current offering on the Luminex LX200 instrument, and GA now has the potential to offer GA-map® platform also to the thousands of diagnostics labs globally that are running these high quality MAGPIX® instruments. The human microbiome market is accelerating both in terms of evidence-based research and pharma products launched. The market's need for a clinical validated microbiome test is growing with this market. Thus, the news that more clinical labs can start microbiome testing with GA-map® on MAGPIX® will fuel this growth and create more business opportunities.Board Change • Nov 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chairperson Kathryn Baker was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元8V8DE BiotechsDE 市場7D-5.3%-1.0%0.6%1Y-68.9%-11.9%0.2%株主還元を見る業界別リターン: 8V8過去 1 年間で-11.9 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 8V8は、過去 1 年間で0.2 % のリターンを上げたGerman市場を下回りました。価格変動Is 8V8's price volatile compared to industry and market?8V8 volatility8V8 Average Weekly Movement68.9%Biotechs Industry Average Movement8.8%Market Average Movement6.1%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: 8V8の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 8V8の 週次ボラティリティ は、過去 1 年間で37%から69%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト200818Ronny Hermansenwww.genetic-analysis.comGenetic Analysis AS社は、科学的根拠に基づく診断会社で、米国、欧州、および国際的なヒトマイクロバイオーム市場向けの診断ソリューションを開発している。ヒトの腸内細菌叢を解析するプラットフォームGA-map、ディスバイオーシスを検出し特徴付けるGA-map Dysbiosis Test、クラウドベースのソフトウェアソリューションGA-map Analyzerを提供している。また、バイオマーカーを検索し、研究結果を検証したり、研究結果をすぐに使用できるルーチン検査プラットフォームに移行したりするためのツールであるGA-map Discovery、核酸分析用の糞便検体の採取、輸送、保管に使用するGA-map Sample Collection Kit、使いやすい家庭用サンプリング手順による非侵襲的検査であるGA-map Covid-19 Fecal Testも提供している。また、ラボラトリーサービス、バイオインフォマティクス解析サービスも提供している。同社は迅速な微生物ベースのPCR検査を開発している。Genetic Analysis AS社は2008年に設立され、本社はノルウェーのオスロにある。もっと見るGenetic Analysis AS 基礎のまとめGenetic Analysis の収益と売上を時価総額と比較するとどうか。8V8 基礎統計学時価総額€42.70m収益（TTM）-€1.06m売上高(TTM)€1.97m1.4xP/Sレシオ-2.5xPER（株価収益率8V8 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計8V8 損益計算書（TTM）収益NOK 21.17m売上原価NOK 4.70m売上総利益NOK 16.47mその他の費用NOK 27.89m収益-NOK 11.41m直近の収益報告Dec 31, 2025次回決算日May 28, 2026一株当たり利益（EPS）-0.17グロス・マージン77.80%純利益率-53.91%有利子負債／自己資本比率16.2%8V8 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 11:43終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genetic Analysis AS 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Gediminas RuginisNorne Securities AS
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Chairman of the Board Morten Jurs was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29Genetic Analysis AS to Report Q1, 2026 Results on May 28, 2026Genetic Analysis AS announced that they will report Q1, 2026 results on May 28, 2026
お知らせ • Mar 13Genetic Analysis AS Launches GA-Map Dysbiosis Test AInsight for AI-Assisted InterpretationGenetic Analysis AS announced the launch of GA-map Dysbiosis Test AInsight, an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice. The GA-map Dysbiosis Test is a CE-marked molecular diagnostic assay designed to profile gut microbiome and evaluate intestinal dysbiosis by comparing a patient's microbiome profile to a healthy reference population. AInsight supports healthcare professionals by structuring microbiome findings and contextualizing deviations in bacterial abundance using curated scientific evidence. The platform utilizes an AI language model to retrieve clinically relevant associations linked to each bacterial marker measured by the GA-map Dysbiosis Test. By simplifying the interpretation of microbiome results, AInsight is expected to support the broader clinical use of the GA-map Dysbiosis Test and contribute to increased demand for GA's reagent kit products. Similar to the GA-map Dysbiosis Test, which operates within a predefined and clinically validated closed diagnostic system, the AI model deployed in AInsight is restricted to retrieving information exclusively from GA's Bacteria Compendium - GA's curated knowledge base. This controlled framework ensures that generated interpretation reports remain aligned with the validated scientific foundation underpinning the GA-map Dysbiosis Test. The addition of AInsight enables automated generation of structured interpretation reports for individual microbiome profiles and supports scalable report generation for laboratory workflows, enabling laboratories to efficiently handle increasing testing volumes. The reports generated by GA-map Dysbiosis Test AInsight are intended to provide informational support and should always be interpreted within the broader clinical context by qualified healthcare professionals. By lowering the barrier to interpreting microbiome test results, AInsight represents an important step in GA's strategy to expand the clinical use of its GA-map diagnostic platform.
お知らせ • Jan 27Genetic Analysis AS to Report Fiscal Year 2025 Results on Feb 25, 2026Genetic Analysis AS announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Feb 25, 2026
お知らせ • Nov 17Genetic Analysis AS Announces Completion of the Biomarker Panel Development in Its Ongoing IBD Precision Dx ProjectGenetic Analysis AS announced the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marks a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development. The goal of the IBD Precision Dx project is to develop a microbiome-based diagnostic test capable of predicting disease course in Ulcerative Colitis (UC) patients, thereby supporting earlier and more targeted treatment decisions. The project is conducted in collaboration with two Scandinavian university hospitals, Akershus University Hospital (AHUS) and University hospital of Gothenburg (UGOT) and supported by funding of approximately EUR 2 million from the Research Council of Norway. GA has now finalized the bacteria biomarker panel design freeze, marking the completion of the assay development phase. The resulting biomarker panel enables analysis of the bacterial profile in stool samples to stratify UC patients according to predicted disease severity. Testing performed using this panel demonstrates strong technical results. GA has extensive experience in IBD research, having been actively involved in the field since 2013. Over the years, the company has built an extensive knowledge base, providing valuable insight that has played a key role in designing and conducting this IBD project, ultimately leading up to the development of the GA-map® IBD Precision Dx. The new assay will leverage GA's proprietary GA-map® technology platform for standardized, multiplex analysis adapted on the Luminex® xMAP® technology. This approach will enable commercialization of the assay on the Lumine xMAP® platform and make it available to laboratories and research users worldwide. Clinical need and market relevance: IBD affects approximately 5-6 million people across the US and Europe and imposes a significant burden on patients and healthcare systems, with annual healthcare costs estimated at EUR 12-13 billion2). Beyond healthcare costs, IBD has profound impacts on patients' quality of life, productivity, and social functioning. More than half of IBD patients are diagnosed with UC3). There is a recognized need for improved tools to support personalized treatment strategies and optimize therapy selection. Currently, no diagnostic tool exists to predict whether an UC patient will experience a mild or severe disease course. As a result, treatment optimization remains an unmet clinical need. Early administration of biologic therapy in high-risk patients is associated with better outcomes, underscoring the importance of early, precise disease course prediction. The GA-map®IBD Precision Dx test aims to fill this gap by enabling personalized treatment strategies and improved patient outcomes.
お知らせ • Oct 29Genetic Analysis AS to Report Q3, 2025 Results on Nov 27, 2025Genetic Analysis AS announced that they will report Q3, 2025 results on Nov 27, 2025
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Chairman of the Board Morten Jurs was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29Genetic Analysis AS to Report Q1, 2026 Results on May 28, 2026Genetic Analysis AS announced that they will report Q1, 2026 results on May 28, 2026
お知らせ • Mar 13Genetic Analysis AS Launches GA-Map Dysbiosis Test AInsight for AI-Assisted InterpretationGenetic Analysis AS announced the launch of GA-map Dysbiosis Test AInsight, an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice. The GA-map Dysbiosis Test is a CE-marked molecular diagnostic assay designed to profile gut microbiome and evaluate intestinal dysbiosis by comparing a patient's microbiome profile to a healthy reference population. AInsight supports healthcare professionals by structuring microbiome findings and contextualizing deviations in bacterial abundance using curated scientific evidence. The platform utilizes an AI language model to retrieve clinically relevant associations linked to each bacterial marker measured by the GA-map Dysbiosis Test. By simplifying the interpretation of microbiome results, AInsight is expected to support the broader clinical use of the GA-map Dysbiosis Test and contribute to increased demand for GA's reagent kit products. Similar to the GA-map Dysbiosis Test, which operates within a predefined and clinically validated closed diagnostic system, the AI model deployed in AInsight is restricted to retrieving information exclusively from GA's Bacteria Compendium - GA's curated knowledge base. This controlled framework ensures that generated interpretation reports remain aligned with the validated scientific foundation underpinning the GA-map Dysbiosis Test. The addition of AInsight enables automated generation of structured interpretation reports for individual microbiome profiles and supports scalable report generation for laboratory workflows, enabling laboratories to efficiently handle increasing testing volumes. The reports generated by GA-map Dysbiosis Test AInsight are intended to provide informational support and should always be interpreted within the broader clinical context by qualified healthcare professionals. By lowering the barrier to interpreting microbiome test results, AInsight represents an important step in GA's strategy to expand the clinical use of its GA-map diagnostic platform.
お知らせ • Jan 27Genetic Analysis AS to Report Fiscal Year 2025 Results on Feb 25, 2026Genetic Analysis AS announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Feb 25, 2026
お知らせ • Nov 17Genetic Analysis AS Announces Completion of the Biomarker Panel Development in Its Ongoing IBD Precision Dx ProjectGenetic Analysis AS announced the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marks a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development. The goal of the IBD Precision Dx project is to develop a microbiome-based diagnostic test capable of predicting disease course in Ulcerative Colitis (UC) patients, thereby supporting earlier and more targeted treatment decisions. The project is conducted in collaboration with two Scandinavian university hospitals, Akershus University Hospital (AHUS) and University hospital of Gothenburg (UGOT) and supported by funding of approximately EUR 2 million from the Research Council of Norway. GA has now finalized the bacteria biomarker panel design freeze, marking the completion of the assay development phase. The resulting biomarker panel enables analysis of the bacterial profile in stool samples to stratify UC patients according to predicted disease severity. Testing performed using this panel demonstrates strong technical results. GA has extensive experience in IBD research, having been actively involved in the field since 2013. Over the years, the company has built an extensive knowledge base, providing valuable insight that has played a key role in designing and conducting this IBD project, ultimately leading up to the development of the GA-map® IBD Precision Dx. The new assay will leverage GA's proprietary GA-map® technology platform for standardized, multiplex analysis adapted on the Luminex® xMAP® technology. This approach will enable commercialization of the assay on the Lumine xMAP® platform and make it available to laboratories and research users worldwide. Clinical need and market relevance: IBD affects approximately 5-6 million people across the US and Europe and imposes a significant burden on patients and healthcare systems, with annual healthcare costs estimated at EUR 12-13 billion2). Beyond healthcare costs, IBD has profound impacts on patients' quality of life, productivity, and social functioning. More than half of IBD patients are diagnosed with UC3). There is a recognized need for improved tools to support personalized treatment strategies and optimize therapy selection. Currently, no diagnostic tool exists to predict whether an UC patient will experience a mild or severe disease course. As a result, treatment optimization remains an unmet clinical need. Early administration of biologic therapy in high-risk patients is associated with better outcomes, underscoring the importance of early, precise disease course prediction. The GA-map®IBD Precision Dx test aims to fill this gap by enabling personalized treatment strategies and improved patient outcomes.
お知らせ • Oct 29Genetic Analysis AS to Report Q3, 2025 Results on Nov 27, 2025Genetic Analysis AS announced that they will report Q3, 2025 results on Nov 27, 2025
お知らせ • Sep 24Genetic Analysis AS Launches GA-map MHI GutHealth Reagent KitGenetic Analysis AS announced the launch of a novel Research Use Only (RUO) reagent kit, the GA-map MHI GutHealth. The test provides an advanced tool for measuring antibiotic-induced microbiome imbalances and has been validated for recurrent Clostridioides difficile infection (rCDI). With this launch, GA-map MHI Gut Health is made available for Luminex xMAP users globally. As communicated on December 20, 2024, GA and Ferring Pharmaceuticals announced a collaboration to develop a new microbiome diagnostic test. Since then, GA has brought together two established technologies - GA's PCR-based microbiome diagnostic platform (GA-map®?1) and Ferring's research-validated biomarker for measuring post-antibiotic microbiome imbalances (the 'Microbiome Health Index(TM)'2). The test utilizes the unique Luminex xMAP®? technology for targeted and effective multiplex analysis, making it readily accessible for LuminexxMAP users worldwide. Initially, GA-map®? MHI GutHealth is targeted towards rCDI patients, providing clinicians with a rapid tool to assess baseline microbiome imbalances and monitor treatment effects during microbiome restoration. The test also has potential as a pharmacodynamic (PD) measure of microbiota restoration in clinical trials for Live Biotherapeutic Products (LBPs), Fecal Microbiota Transplants (FMTs), and other microbiome restoration approaches. This is relevant in all clinical trials where antibiotic-associated microbiome imbalances play a critical role, such as Graft-versus-Host Disease (GvHD), infectious diseases, immunocompromised patients, and MDRO-colonized patients3. With the launch of the GA-map®?MHI GutHealth test, GA expands into a novel diagnostic field. The market potential for a diagnostic test aiding treatment and follow-up of rCDI is significant, with close to 500,000 annual CDI cases in the US alone4. Thus, the test will contribute to Genetic Analysis' commercial activities and provide incremental contribution to the Company's revenue base.
お知らせ • Jul 31Genetic Analysis AS and Pangea Laboratory LLC Announces the Launch of GA-Map MHI GutHealth in the USAGenetic Analysis AS and Pangea Laboratory LLC announced the launch of the GA-map MHI GutHealth as a Research Use Only (RUO) test in the USA. As part of the collaboration Pangea will perform analysis in their CLIA-certified, CAP-accredited laboratory in Tustin, California. The GA-map MH I GutHealth is the first microbiome-based diagnostic test providing clinically actionable insights into antibiotic-induced microbiome imbalances. The test has been developed by GA in collaboration with Ferring Pharmaceuticals and combines GA's proprietary GA-map technology with Ferring's Microbiome Health Index(TM). MHI is a validated biomarker measuring the ratio of pro-inflammatory versus anti-inflammatory bacteria in the patient's gut, demonstrated in recurrent Clostridioides difficile (rCDI) infected patients. Initially the test will be targeted towards patients with rCDI, providing clinicians with a rapid tool for baseline microbiome imbalance assessment and for monitoring the effect during microbiome restoration treatment. rCDI infection impacts approximately 500,000 patients annually in the United States, and up to 35% of initial CDI cases will experience a recurrence, which is associated with up to 30,000 deaths annually. Beyond rCDI, the test has the potential to support clinical decision-making in patient groups where antibiotic-associated microbiome imbalance plays a critical role.raft-versus-Host Disease (GvHD), infectious diseases, immunocompromised patients and patients colonized with multidrug-resistant organisms. The test will now be available for analysis at Pangea. As part of the collaboration, GA will supply reagent kits to Pangea. The agreement outlines an ongoing partnership without predefined order volumes or minimum delivery commitments. Revenues for GA will be generated based on the number of tests sold. GA is not obliged to make any additional financial investments as part of the collaboration.
お知らせ • Jul 28Genetic Analysis AS to Report Q2, 2025 Results on Aug 27, 2025Genetic Analysis AS announced that they will report Q2, 2025 results on Aug 27, 2025
お知らせ • Jun 17Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 4.139347 million.Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 4.139347 million. Security Name: Shares Security Type: Common Stock Securities Offered: 4,813,194 Price\Range: NOK 0.86 Transaction Features: Rights Offering
お知らせ • May 28Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of SEK 7.1 million.Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of SEK 7.1 million. Security Name: Shares Security Type: Common Stock Securities Offered: 8,255,814 Price\Range: SEK 0.86 Transaction Features: Rights Offering
お知らせ • May 06Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 12.805035 million.Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 12.805035 million. Security Name: Shares Security Type: Common Stock Securities Offered: 14,889,576 Price\Range: NOK 0.86 Transaction Features: Subsequent Direct Listing
お知らせ • May 05Genetic Analysis as Announces Stepping Down of Jethro Holter as Current ChairmanGenetic Analysis AS announced that Dr. Jethro Holter, the current Chairman, to step down from his role and not seek re-election. Dr. Holter will be focusing on his new position as CEO of AdjuTec Pharma.
お知らせ • Apr 28Genetic Analysis AS to Report Q1, 2025 Results on May 27, 2025Genetic Analysis AS announced that they will report Q1, 2025 results on May 27, 2025
お知らせ • Apr 22Genetic Analysis AS and Thalys Medical Technology Group Announce the Launch of A Microbiome Test to the Chinese Consumer Health MarketGenetic Analysis AS ("GA") and Thalys Medical Technology Group Corporation ("Thalys") announced the launch of a microbiome test for the Consumer Health (D2C) market in China. The test is based on GA's clinically validated microbiome test, the GA-map® Dysbiosis Test, but specifically adapted to suit the Chinese market. This strategic cooperation represents the launch of GA's commercial presence in the fast-growing market Chinese market via its partner Thalys and their new Independent Clinical Lab (ICL) in Shanghai. The Chinese D2C microbiome testing market is growing rapidly. The estimated market size in 2023 was ~USD50-80 million, and with a projected CAGR of 20-30%, it has an expected 2030 Market Size of USD200-300 million. Main growth drivers include increased consumer interest in gut health, probiotics and personalized nutrition, as well as advances in e-commerce & digital health platforms such as Tmall and WeChat. The Thalys microbiome testing service powered by the GA-map® Dysbiosis Test will provide consumers in China with a fast and affordable test. Thalys has developed a D2C mobile software where customers can easily subscribe, pay and view report results on their mobile phones. The results will offer insights into the beneficial and potentially harmful microbes present in the gut, along with potential health- and wellness implications. Test results will include personalized probiotics recommendations as well as weight management & metabolic health insights. The upcoming launch of the GA-map® Dysbiosis Test to the Chinese Consumer Health market marks the completion of the first stage of the Thalys and GA collaboration. Moving forward, the Thalys Group will further develop and distribute tests based on GA's GA-map® Technology in China. Within the framework of the cooperation, GA will supply reagent kits to Thalys. Thalys has invested in the clinical study activities associated with the project and developing front-end consumer software solutions, whereas GA has contributed its proprietary software and algorithm development from internal resources. The agreement set out for the cooperation is structured as an ongoing partnership without predefined order volumes or minimum delivery commitments, but revenues will be generated for GA based on the number of tests sold. GA is not obliged to make any additional financial investments as part of the collaboration.
お知らせ • Jan 28Genetic Analysis AS to Report Fiscal Year 2024 Results on Feb 26, 2025Genetic Analysis AS announced that they will report fiscal year 2024 results on Feb 26, 2025
Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.065 loss per share (vs kr0.17 loss in 3Q 2023)Third quarter 2024 results: kr0.065 loss per share (improved from kr0.17 loss in 3Q 2023). Revenue: kr3.62m (down 24% from 3Q 2023). Net loss: kr3.23m (loss narrowed 25% from 3Q 2023).
お知らせ • Oct 17Genetic Analysis AS to Report Q3, 2024 Results on Nov 15, 2024Genetic Analysis AS announced that they will report Q3, 2024 results on Nov 15, 2024
お知らせ • Aug 01Genetic Analysis AS to Report Q2, 2024 Results on Aug 30, 2024Genetic Analysis AS announced that they will report Q2, 2024 results on Aug 30, 2024
お知らせ • Jun 09Genetic Analysis as Announces Resignation of Eilert Aamodt as Chief Financial OfficerMicrobiome DX company Genetic Analysis AS announced that Eilert Aamodt has decided to resign as CFO to take on a new position in another company and industry. He will remain in his current role until the end of August 2024, ensuring a smooth and efficient transition for GA. Aamodt has been with GA since February 2021, and GA has initiated a process to recruit his replacement.
Reported Earnings • May 30First quarter 2024 earnings released: kr0.14 loss per share (vs kr0.29 loss in 1Q 2023)First quarter 2024 results: kr0.14 loss per share (improved from kr0.29 loss in 1Q 2023). Revenue: kr4.77m (down 25% from 1Q 2023). Net loss: kr5.80m (loss narrowed 21% from 1Q 2023).
お知らせ • May 01Genetic Analysis AS to Report Q1, 2024 Results on May 29, 2024Genetic Analysis AS announced that they will report Q1, 2024 results on May 29, 2024
Reported Earnings • Apr 22Full year 2023 earnings released: kr0.62 loss per share (vs kr1.13 loss in FY 2022)Full year 2023 results: kr0.62 loss per share (improved from kr1.13 loss in FY 2022). Revenue: kr23.2m (up 12% from FY 2022). Net loss: kr23.8m (loss narrowed 16% from FY 2022).
お知らせ • Apr 16Genetic Analysis AS, Annual General Meeting, May 14, 2024Genetic Analysis AS, Annual General Meeting, May 14, 2024.
New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Market cap is less than US$10m (€2.18m market cap, or US$2.36m). Minor Risk Revenue is less than US$5m (kr23m revenue, or US$2.2m).
お知らせ • Jan 31Genetic Analysis AS to Report Fiscal Year 2023 Results on Feb 29, 2024Genetic Analysis AS announced that they will report fiscal year 2023 results on Feb 29, 2024
お知らせ • Dec 23Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 3.235125 million.Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 3.235125 million. Security Name: Shares Security Type: Common Stock Securities Offered: 4,095,095 Price\Range: NOK 0.79 Transaction Features: Rights Offering
New Risk • Nov 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 9.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (€2.99m market cap, or US$3.20m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m).
お知らせ • Nov 05Genetic Analysis AS Provides Earnings Guidance for the Year 2023, 2024, and 2025Genetic Analysis AS provided earnings guidance for the year 2023, 2024, and 2025. For 2023, the company expects Operating income of approximately NOK 20 million- NOK 25 million.For 2024, the company expects Operating income of approximately NOK 25 million - NOK 35 million.For 2025, the company expects Operating income of approximately NOK 40 million -NOK 60 million as well as positive cash flow.
お知らせ • Nov 04Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of NOK 9 million.Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of NOK 9 million. Security Name: Shares Security Type: Common Stock Securities Offered: 11,392,405 Price\Range: NOK 0.79 Transaction Features: Rights Offering
Reported Earnings • Nov 04Third quarter 2023 earnings released: kr0.17 loss per share (vs kr0.27 loss in 3Q 2022)Third quarter 2023 results: kr0.17 loss per share (improved from kr0.27 loss in 3Q 2022). Revenue: kr4.73m (flat on 3Q 2022). Net loss: kr4.32m (loss narrowed 35% from 3Q 2022).
お知らせ • Nov 03Genetic Analysis AS Announces Resignation of Staffan Strömberg from the Board of DirectorsGenetic Analysis AS announced that the board member Staffan Strömberg has resigned from the Board of Directors ("BoD") at his request, due to high workload, with immediate effect.
お知らせ • Oct 24Genetic Analysis AS Launches the GA-map® Discovery - New Microbiome Profiling Service Offering Directed to Research Customers in the Academia and Microbiome IndustryGenetic Analysis AS announced that the Company launches the GA-map® Discovery - a new microbiome profiling service offering directed to research customers in the academia and microbiome industry. The GA-map® Discovery is GA's first dedicated offering in the research market which is currently witnessing considerable growth - cementing GA's position as a pioneer in microbiome disease diagnostics. Built on the standardized GA-map® platform, GA-map® Discovery is a comprehensive end-to-end microbiota research service for gut and oral microbiota profiling. Comprising more than 170 bacteria markers, the GA-map® Discovery was developed to facilitate the discovery of new biomarkers and bacteria signatures associated with health and disease. GA-map® Discovery is a perfect choice for comparative studies of different disease cohorts, treatment responses, and more. The launch of GA-map ® Discovery brings to the market a research service with high accuracy, exceptional reproducibility, and short turnaround time, enabling cost-effective microbiota measurements. The GA-map® Discovery is GA's first dedicated offering in the research market. In recent years, microbiome research has witnessed considerable growth, fuelling new inventions in disease diagnostics, treatment selection and monitoring, and disease prevention. The research market for microbiome measurement was valued at $859 million in 2021 and is projected to reach $3,417 million by 2031.
お知らせ • Oct 18Genetic Analysis AS to Report Nine Months, 2023 Results on Nov 16, 2023Genetic Analysis AS announced that they will report nine months, 2023 results on Nov 16, 2023
New Risk • Oct 12New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr20m free cash flow). Share price has been highly volatile over the past 3 months (9.0% average weekly change). Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (€2.33m market cap, or US$2.45m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.1m).
Reported Earnings • Sep 01Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.24 loss in 2Q 2022)Second quarter 2023 results: kr0.22 loss per share (improved from kr0.24 loss in 2Q 2022). Revenue: kr5.70m (up 4.0% from 2Q 2022). Net loss: kr5.49m (loss narrowed 9.4% from 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
お知らせ • Aug 01Genetic Analysis AS to Report Q2, 2023 Results on Aug 30, 2023Genetic Analysis AS announced that they will report Q2, 2023 results on Aug 30, 2023
お知らせ • May 12Genetic Analysis AS Announces Changes in Members of Nomination CommitteeGenetic Analysis AS held its Annual General Meeting on May 11, 2023 approved Svein Lien and Eilert Aamodt were elected as members of nomination committee.
Breakeven Date Change • Apr 25Forecast breakeven date pushed back to 2025The analyst covering Genetic Analysis previously expected the company to break even in 2024. New forecast suggests losses will reduce by 58% per year to 2024. The company is expected to make a profit of kr4.00m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 13Forecast breakeven date pushed back to 2025The analyst covering Genetic Analysis previously expected the company to break even in 2024. New forecast suggests losses will reduce by 58% per year to 2024. The company is expected to make a profit of kr4.00m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule.
Reported Earnings • Feb 18Full year 2022 earnings released: kr1.14 loss per share (vs kr1.16 loss in FY 2021)Full year 2022 results: kr1.14 loss per share (improved from kr1.16 loss in FY 2021). Revenue: kr20.7m (up 55% from FY 2021). Net loss: kr28.3m (loss narrowed 2.5% from FY 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.
お知らせ • Feb 17Genetic Analysis AS, Annual General Meeting, May 11, 2023Genetic Analysis AS, Annual General Meeting, May 11, 2023.
お知らせ • Jan 31Genetic Analysis AS Announces Executive ChangesGenetic Analysis AS announce that GA is strengthening and future-proofing the organization within business development, sales, andproduct development to be better positioned to harvest opportunities in the microbiome market. As diagnostics is now becoming a vital part of the treatment regime for gastroenterological disorders, GA believes that the microbiome diagnostic market will continue to rapidly increase in the coming years. Following the recent regulatory approval of microbiome-altering drugs in the US, GA also sees a significant increase in opportunitiesto add several new markers on the GA-map® platform. GA announce that GA's Chief Technology Officer Kari Furu has accepted the new position as Head of Business and Product Development. Kari and GA's development teams have developed innovative products for GA, and its product development within IBD attracted strong interest recently as a finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD. GA announce that Ms. Pranvera Hiseni has accepted the position of Development Manager, reporting to the Head of Business and Product Development, where she will be responsible for GA's development projects. Pranvera has worked in GA's development department with a key focus on platform development and has also been instrumental in building up the HumGut Database, a comprehensive human gut metagenome collection. After the implementation of the new organization, the management team will consist of: Ronny Hermansen (CEO); Eilert Aamodt (CFO); Cristina Casén (Senior VP Clinical & Medical Affairs); Lars Tiller (Head of Operations); Kari Furu (Head of Business and Product Development); Detlef Janke (Commercial Director). With these new organizational changes, the previous responsibilities of the CTO and CCO will be implemented under the Product and Software development team and the clinical team. The new organization will be implemented immediately.
お知らせ • Jan 20Genetic Analysis as Achieves Thai Fda License for Ga-Map[®] Dysbiosis Test in ThailandGenetic Analysis AS ("GA") announced that Thailand Food and Drug Administration ("Thai FDA") authority have granted GA license for the GA-map® Dysbiosis Test in Thailand. GA has, in cooperation with its distributor Hausen Bernstein Co. Ltd. ("HB") filed for regulatory approval of the GA-map® Dysbiosis Test in 2022, and announce that the test has now been approved by the Thai FDA authorities for Clinical use in IBS and IBD patients. HB plans to launch the GA-map from their molecular lab in Bangkok and market the GA-map® products in wider Thailand. The market demand for gut microbiome assessments is rapidly increasing globally in private healthcare services, medical clinics, and academic research with a focus on identifying and categorizing the patient's microbiota. Together with HB, GA can now offer its Thai FDA-approved standardised gut microbiome testing platform to the Thai market to meet the growing interest and raise awareness of dysbiosis.
お知らせ • Jan 19Genetic Analysis AS to Report Fiscal Year 2022 Results on Feb 17, 2023Genetic Analysis AS announced that they will report fiscal year 2022 results on Feb 17, 2023
Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 8 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Anne Camilla Bondesson is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Nov 06Third quarter 2022 earnings released: kr0.27 loss per share (vs kr0.28 loss in 3Q 2021)Third quarter 2022 results: kr0.27 loss per share (improved from kr0.28 loss in 3Q 2021). Revenue: kr4.77m (up 106% from 3Q 2021). Net loss: kr6.68m (loss narrowed 2.3% from 3Q 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Aug 20Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr5.48m (up 177% from 2Q 2021). Net loss: kr6.06m (loss narrowed 12% from 2Q 2021). Over the next year, revenue is forecast to grow 62%, compared to a 10% growth forecast for the Biotechs industry in Germany.
お知らせ • May 02Genetic Analysis AS Announces Board ChangesGenetic Analysis AS at the AGM held on April 28, 2022, elected Per Matsson as Chairperson, Andrew Stapleton as Board member, Thorvald Steen as member of nomination committee.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chairperson Kathryn Baker was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 06Genetic Analysis Strengthens Its Management Team by Hiring Head of OperationsMicrobiome DX company Genetic Analysis AS announces that the Company has strengthened its management team by hiring Mr. Lars Tiller as Head of Operations. Lars Tiller will be responsible for manufacturing and logistics activities in GA. As a result of the increased market demand for the GA-map diagnostic kits, GA has now strengthened its organisation with expertise and know-how from scale-up in the fast-growing diagnostic industry. As Head of Operations, Mr. Lars Tiller will be responsible for manufacturing and logistics and will focus on production efficiency to secure that the Company is able to meet future manufacturing capacity in a cost-efficient way.
Reported Earnings • Feb 20Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr1.16 loss per share (up from kr1.29 loss in FY 2020). Revenue: kr13.4m (up 78% from FY 2020). Net loss: kr29.0m (loss widened 31% from FY 2020). Revenue was in line with analyst estimates.
お知らせ • Feb 01Genetic Analysis as Launches on a New Technology Platform, GA-map® Dysbiosis Test KitMicrobiome DX company Genetic Analysis AS launches GA-map® on a new platform; MAGPIX®. The MAGPIX® instrument is the most affordable instrument of the Luminex's xMAP® instruments and it enables up to 50 plex using MagPlex® Microspheres. The MAGPIX® system is already a widely used platform and a large number of laboratories have already installed this system for performing other tests. To launch the GA-map® Test on a new readout system will capture the large number of labs already having the system installed, and thus be of great importance for significantly increasing the addressable market for high precision GA-map® Microbiome test. The more affordable MAGPIX® system will also increase the market size for GA in terms of lowering the cost barrier to install the test platform. Potential customers have for some years asked for GA-map® on the MAGPIX® instrument system and GA has now completed the develop and CE-marked the GA-map® Test on this well-known and easy to use instrument. This will complement GA's current offering on the Luminex LX200 instrument, and GA now has the potential to offer GA-map® platform also to the thousands of diagnostics labs globally that are running these high quality MAGPIX® instruments. The human microbiome market is accelerating both in terms of evidence-based research and pharma products launched. The market's need for a clinical validated microbiome test is growing with this market. Thus, the news that more clinical labs can start microbiome testing with GA-map® on MAGPIX® will fuel this growth and create more business opportunities.
Board Change • Nov 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chairperson Kathryn Baker was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
